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ABSTRACT
EGFR is an extensively studied biomarker in head and neck squamous cell 
carcinoma (HNSCC). In this review, we discuss the prognostic and predictive 
role of EGFR in HNSCC, focusing on the different molecular alterations in specific 
treatment modalities such as radiotherapy alone (RT), combination of surgery, RT 
and chemotherapy (CT), EGFR inhibitors. We considered EGFR at different molecular 
levels: protein expression, protein activation, gene copy number, polymorphisms, 
mutation, EGFRvIII expression and EGFR ligand expression. 
Considering RT alone, evidence supports the predictive and prognostic role of 
high EGFR expression only when evaluated by quantitative assays: this may help 
select the patients who can mostly benefit from accelerated treatment. Conversely, 
no predictive biomarkers are available when treatment is a combination of surgery, 
CT and RT. For this combined treatment, several studies indicate that EGFR expression 
represents a good prognostic parameter only when measured by a “quantitative” 
or at least semi-quantitative method. With respect to EGFR inhibitors, neither EGFR 
expression nor increased gene copy number represent prognostic/predictive factors. 
If validated, nuclear EGFR, TGFα levels, EGFR phopshorylation and polymorphisms 
could represent additional prognostic factors in relation to combination of surgery, 
CT and RT, while EGFR polymorphisms and high amphiregulin levels could have 
prognostic value in patients treated with EGFR inhibitors. 
INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) 
represents the sixth most frequent cancer worldwide with 
an incidence of 560,000 cases/year and over 350,000 
deaths annually [1]. Treatment of locally-advanced 
HNSCC requires a multidisciplinary approach involving 
surgery followed by radiation (RT) with or without 
chemotherapy (CT) or curative RT with concomitant CT 
or anti-EGFR agents. TP53 gene status [2, 3] and HPV 
[4] are the most studied biological markers with known 
prognostic value. The extensive studies of HPV have 
paved the way for tailored therapeutic strategies, with 
the aim of sparing toxicities in HPV-positive tumors and 
intensifying treatment in HPV-negative cancers.
As observed also for other malignancies, an 
extensively studied biomarker in HNSCC is the epidermal 
growth factor receptor (EGFR), a cell surface receptor 
member of the ErbB family. Activation of EGFR leads 
to a phosphorylation cascade mediated via tyrosine 
kinases which works downstream through the PI3K–
PTEN–AKT, MAPK, ERK, and Jak/STAT pathways 
and promotes proliferation, invasion, angiogenesis, 
and metastatic spread. Evidence of EGFR activity has 
been reported in HNSCC cell lines, as well as in a high 
percentage of primary HNSCC [5-7]. Aberrant activation 
of EGFR signaling in HNSCC may be achieved by several 
mechanisms, including overexpression of EGFR and its 
ligands, establishing autocrine/paracrine loops, EGFR 
gene amplification, EGFR mutation/polymorphism and 
transactivation by other receptor tyrosine kinases (RTKs). 
The relevance of EGFR pathway in HNSCC led to the 
successful development of cetuximab in both the curative 
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Table 1: Main studies on EGFR protein expression as prognostic and predictive factor in HSCC.
Study Population Treatment Method Prognostic value of high EGFR
Predictive value 
of high EGFR
Radiotherapy
Chang 2008 n=50, glottic SCC Primary conventional fractionated or hypofractionated RT IHC assay
Impact on recurrence, 
TTP -
Parik 2007 n=123, laryngeal SCC Primary RT IHC assay No impact on OS, LRR -
Wen 1996 n=68, laryngeal SCC RT IHC assay No impact on OS, RR -
Nichols 2012 n=75, laryngeal SCC RT IHC assay No impact on OS, LRR -
Aebersold 2002 n=95, oropharyngeal SCC primary RT IHC assay No impact on OS, DFS, LTC -
Lassen 2013 n=336, oropharyngeal SCC primary RT IHC assay No impact on OS, DFS, LRC -
Ryott 2009 n=78, oral tongue SCC Preoperative RT IHC assay No impact on pCR -
Ang 2002 n=155, HNSCC primary RT SAMBA system Impact on OS, DFS, LRR -
Chung 2011 n=533, HNSCC Accelerated or standard fractionated RT SAMBA system
Impact on OS, LRR, PFS 
in both arms
No impact on 
OS, PFS, LRR in 
accelerated RT 
arm
Bentzen 2005 n=304 HNSCC CHART vs conventional fractionated RT IHC assay -
Impact on LRC in 
the CHART arm
Eriksen 2005 n=209, supraglottic larynx SCC
Primary RT, OTT: 9½, 6½ or 5½ 
weeks IHC assay -
Impact on LRC 
in the arms with 
OTT 6½ or 5½ 
weeks
Surgery, chemotherapy, radiotherapy
Ranelletti 2001 Laryngeal SCC Surgery +/- RT Binding assay Impact on OS -
Dassonville 1993 n=109, HNSCC CT Binding assay Impact on OS, relapse free -
Magné 2001 n=77, oro and hypopharynx SCC Non accelerated RT+CT Binding assay Impact on OS, TTF -
Etienne 1999 n=82, advanced HNSCC Preoperative CT +/- RT Binding assay Impact on OS -
Pivot 2005 n=71, hypo and larynx SCC Preoperative CT; primary RT Binding assay Impact on OS, DFS -
Almadori 1999 n=140 laryngeal SCC Surgery +/- RT Binding assay Impact on neck node relapse -
Maiorano 1998 N=100 oral cavity SCC surgery IHC assay Impact on DFS, OS
Grandis 1998 n=91, HNSCC Surgery +/- RT +/- CT SAMBA system Impact on DFS -
Psyrri 2005 n=67, oropharyngeal SCC Primary RT; surgery and RT +/- CT AQUA
Impact on response 
(nuclear EGFR), LRR, 
DFS
-
Pectasides 2011 n=64, HNSCC Primary RT or surgery + RT AQUA Impact on OS -
Szabo 2011 n=71, HNSCC Surgery IHC assay Impact on OS -
Kontic 2015 n=185, laryngeal SCC surgery IHC assay Impact on OS -
Huang 2012 n=160, oral cavity SCC surgery IHC assay Impact on DFS, OS -
Monteiro 20012 n=67, oral cavity SCC Surgery +/- RT IHC assay Impact on OS, DFS -
Farhadied 2009 n=106 ,laryngeal SCC Surgery +/- RT IHC assay Impact on OS; DFS; LRR -
Laimer 2007 n=109, oral and oropharyngeal SCC Surgery +/- CT +/-RT IHC assay Impact on OS -
Wheeler 2012 n=154, HNSCC Surgery +/- RT or CRT IHC assay Impact on OS, PFS -
Lindquist 2012 n=62, oropharyngeal SCC Preoperative RT +/- surgery IHC assay Impact on OS -
Jiang 2009 Laryngeal SCC Surgery + RT IHC assay No impact on OS LRC -
Nakata 2011 n=89, oral tongue SCC Surgery IHC assay No impact on DFS and OS -
Lundberg 2012 n=130, HNSCC Surgery +/- RT +/- CT IHC assay No impact on DFS -
Ongkeko 2005 n=44, pharynx and larynx SCC Surgery IHC assay No impact on DFS -
Carracedo 2008 n=47, pharynx and larynx SCC Surgery IHC assay No impact on OS, relapse -
Won 2012 n=121, oral and oropharyn-geal SCC Surgery +/- RT +/- CT IHC assay No impact on RFS -
Trivedi 2011 n=135, oral SCC Surgery +/- RT +/- CT IHC assay No impact on OS, RFS -
Shah 2009 n=89, oral SCC Surgery +/- RT +/- CT IHC assay No impact on OS, RFS -
Diniz.feitas 2007 n=44, oral SCC surgery IHC assay No impact on OS -
Shiraki 2005 n=140, oral SCC surgery IHC assay No impact on OS -
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and palliative settings [8, 9] and to the conduction of 
several trials with other antibodies directed against EGFR, 
such as panitumumab, zalutumumab and nimotuzumab 
[10-13], or RTK inhibitors involving downstream EGFR 
signaling [14, 15]. 
Several studies have investigated the prognostic and 
predictive value of EGFR in HNSCC. In this review, we 
discuss available evidence on this topic, focusing on the 
different EGFR molecular alterations in tumor tissue, in 
relation with different treatments and settings. 
SEARCH CRITERIA
To identify the key publications on EGFR 
prognostic or predictive value in HNSCC, we conducted 
a comprehensive literature search in the online database 
Medline. The search was last updated on October 2015 
and included only articles in English, with no limitation on 
the publication date. Articles were selected for inclusion 
and assigned to each single treatment section, as judged 
by the Authors.
Clinical outcome was evaluated in terms of clinical 
response, overall survival (OS), progression-free survival 
(PFS), disease-free survival (DFS), locoregional control 
(LRC), locoregional relapse (LRR), locoregional failure 
(LRF), disease control rate (DCR) or time to treatment 
failure (TTF), depending on the reported results of 
considered studies.
A prognostic biomarker was defined as any tumor 
characteristic that informs about cancer outcome. In 
more detail, a biomarker was defined as prognostic when 
patients with tumor showing a specific characteristic 
Rahimi 2012 n=106, oropharyngeal SCC IMRT+ CT IHC assay No impact on OS, DFS, LRC -
Szentkuti 2015 n=226, HNSCC unknown IHC assay No impact on OS -
Keren 2014 Meta-analysis 37 studies Surgery +/-RT+/-CT IHC assay Impact on OS -
Numico 2010 n=122, HNSCC CT or surgery +CT IHC assay No impact on OS, PFS, LRC -
Perisanidis 2013 n=113, oropharyngeal SCC Preoperative CRT + surgery IHC assay No impact on OS, response -
Kumar 2008 n=50, oropharyngeal SCC Preoperative CT+/-RT IHC assay Impact on response to induction CT, OS, DSS -
Hitt 2005 n=46, HNSCC Preoperative CT IHC assay Impact on DFS and OS -
Hong 2010 n=270, oropharyngeal SCC Surgery; RT; surgery + RT IHC assay Impact on LRF -
Reimers 2007 n=80, oropharyngeal SCC Surgery + RT; CRT IHC assay No impact on DFS, OS -
Young 2011 n=240, HNSCC CRT IHC assay No impact on FFS, OS -
Shi 2009 n=111, oropharyngeal SCC RT; CRT IHC assay No impact on OS, DFS -
Kong 2009 n=82, HNSCC RT; CRT; surgery +/- RT+/-CRT IHC assay Impact on OS -
Vainshtein 2014 n=198, oropharyngeal SCC CRT IHC assay No impact on LRF -
EGFR inhibitors
Hitt 2012 n=33, recurrent and/or metastatic HNSCC Paclitaxel + Cetuximab IHC assay
No impact on response, 
PFS, OS -
Tinhofer 2011 n=47, recurrent and/or metastatic HNSCC Docetaxel + cetuximab IHC assay
No impact on DCR, 
PFS, OS -
Psyrri 2005 n=57, HNSCC CT +/- cetuximab IHC assay No impact on OS, PFS
Impact on 
response to cetux-
imab
Ang 2014 n=380 HNSCC CRT+/- cetuximab IHC assay No impact on PFS, OS, LRF -
Wheeler 2012 n=39, recurrent/metastatic HNSCC
Cisplatin, docetaxel and Cetuximab 
+ RT IHC assay Impact on OS -
Smilek 2012 n=29, HNSCC RT+ cetuximab Real time PCR Impact on pCR -
Psyrri 2014 n=63, HNSCC CT+cetuximab+CRT AQUA No impact on OS, PFS -
Burtness 2005 n=117,HNSCC Cisplatin +/-Cetuximab IHC assay -
Impact on 
response. No im-
pact on PFS,OS
Licitra 2012 n=411, recurrent and/or metastatic HNSCC
Cisplatin or carboplatin, 5FU +/- 
cetuximab IHC assay -
No impact on OS, 
response, PFS
Basavaraj 2010 n=92, HNSCC Cisplatin +/- nimotuzumab IHC assay Impact on OS -
Crombet 2004 n=24, HNSCC RT+nimotuzumab IHC assay No impact on OS -
Rodriguez 2010 N=55, HNSCC RT +/- nimotuzumab IHC assay - Impact on OS
HNSCC: head and neck squamous cell carcinoma; OS: overall survival; PFS: progression free survival; RT: radiotherapy: 
CT: chemotherapy: CRT: chemotherapy; IHC: immunohistochemistry; IMRT: intensity modulated RT; RR: recurrence rate: 
LRR: locoregional relapse; LTC: local tumor control; TTF: time to treatment failure; pCR: pathological complete response; 
DSS: disease specific survival; RFS: relapse free survival ; -: the prognostic or predictive value of high EGFR expression was 
not investigated.
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have different survival than subjects without that specific 
characteristic, independently from the treatment [16]. A 
predictive biomarker was defined as a tumor characteristic 
that can be used to predict the tumor response to a specific 
treatment. In particular, the biomarker is considered 
predictive if the treatment effect is different for patients 
with tumor showing a specific characteristic compared 
with patients without that specific characteristic [16]. 
Therefore, a predictive biomarker can be evaluated only 
in head-to-head studies presenting both treated and control 
arms. 
In our analysis we considered EGFR at different 
cytogenetic/molecular levels: protein expression, protein 
activation, gene copy number, polymorphisms, mutation, 
EGFRvIII expression and EGFR ligand expression. From 
identified papers we retrieved prognostic and predictive 
information regarding EGFR alterations according to 
the treatment provided. Treatments were grouped as: 
radiotherapy alone (RT); combination of surgery, RT and 
chemotherapy (CT); EGFR inhibitors. 
CLINICAL EVIDENCE
EGFR PROTEIN EXPRESSION 
Methods of assessment
The expression of EGFR protein has been evaluated 
by several means (Table 1). EGFR immunohistochemistry 
(IHC), a relatively easy and inexpensive technique, 
represents the most frequent option; moreover, tissue 
microarrays enable multiple samples to be stained at 
once, favoring investigation of biomarkers in large case 
series of IHC. However, in available studies, EGFR 
immunoreactivity was heterogeneously evaluated using 
different cut-off values and following different criteria 
for intensity and/or extent of the staining, as well as 
cytoplasmic and/or membranous staining. 
Quantitative in situ molecular-based methods have 
been developed to define EGFR expression by IHC thus 
avoiding the subjectivity of visual assessment. Another 
way of determining EGFR expression is the binding assay, 
a less-used method based on frozen samples processed 
with radioactive labeled EGF and used to estimate EGFR 
concentration.
1A) RADIOTHERAPY 
Prognosis
Four different studies [17-20] investigated EGFR 
expression, evaluated by IHC in laryngeal SCCs treated 
exclusively with primary RT, as prognostic factor. All but 
one of these studies reported no association between high 
EGFR expression and OS or LRC [18-20]. 
Similarly, an intense EGFR expression assessed by 
IHC did not influence LRC, DFS and OS in two different 
series of oropharyngeal SCC patients treated with primary 
RT [21,22], as well as in response of oral tongue SCCs 
treated with preoperative RT [23].
By contrast, in two HNSCC series not differentiated 
by subsite and treated with exclusive RT, EGFR 
expression was a robust prognostic factor only when 
a “quantitative” EGFR image analysis-based IHC 
assay was performed. In one study, EGFR expression, 
quantitatively evaluated by using the SAMBA system, 
was a strong independent prognostic indicator, capable 
to improve the estimation of OS, DFS and LRC applied 
to pretreatment biopsy specimens from patients assigned 
to the standard therapy arm receiving conventional RT 
[24]. The same “quantitative” approach was used in a 
series of HNSCC patients enrolled into a Phase III trial 
who received accelerated or standard fractionated RT 
[25]. Regardless of treatment modalities, high EGFR 
expression was associated with higher LRR (Relative 
Risk: 1.91, P=0.0163) and lower OS (Relative Risk: 1.90, 
P=0.0010). Collectively, these findings show that high 
EGFR expression assessed by a quantitative method might 
Table 2: Main studies on EGFR protein activation as prognostic factor in HSCC
Study Population Treatment EGFR assay Prognostic value of EGFR activation
Radiotherapy
Romanitan 2013 n=8, oropharyngeal SCC Accelerated RT IHC assay No impact on OS, DFS
Surgery, chemotherapy, radiotherapy
Wheeler 2012 n=67 frozen HNSCC Surgery Reverse-phase protein array Impact on PFS
Hama 2009 n=82, frozen HNSCC Surgery +/- CRT Western blotting Impact on relapse
Kong 2006 n=286 HNSCC Surgery +/-RT FRET Impact on DFS
Szabo 2011 n=71, HNSCC surgery IHC assay Impact on OS
HNSCC: head and neck squamous cell carcinoma; OS: overall survival; PFS: progression free survival; RT: radiotherapy: 
CRT: chemotherapy; IHC: immunohistochemistry; DFS: disease free survival; FRET: fluorescence resonance energy transfer 
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be a prognostic marker associated with poor outcome of 
HNSCC patients treated exclusively with RT.
Prediction
In a series of HNSCC patients enrolled into a Phase 
III trial who received accelerated or standard fractionated 
RT, high EGFR expression (quantitatively assessed) 
showed a trend as independent determinant of OS [hazard 
ratio (95% CI for interaction): 0.75 (0.45-1.25)], PFS 
(hazard ratio (95% CI for interaction): 0.77 (0.45-1.31) 
and LRR (hazard ratio (95% CI for interaction): 0.88 
(0.46-1.71)] in the accelerated arm, although statistical 
significance was not reached [25]. Once again, IHC 
analysis performed in pretreatment tumor biopsies 
from HNSCC patients revealed a beneficial role of high 
EGFR expression in patients assigned to continuous 
hyperfractionated accelerated RT (CHART) compared 
with conventionally-fractionated RT [26]. Particularly, 
among patients showing high EGFR expression (cells 
with EGFR membrane staining ≥25%), a significant 
benefit in 3-year LRC rate was observed in the CHART 
arm compared with the conventionally-fractionated RT 
arm. No difference between the two treatment arms was 
observed in the low EGFR expressing group. However, 
EGFR expression had no significant effect on OS or 
distant metastases [26]. 
Another study suggests the predictive value of 
EGFR expression in HNSCC patients treated exclusively 
with RT [27]. Patients with supraglottic larynx SCC were 
treated with primary RT at the same total dose but with 
different OTT: 9½ weeks, 6½ weeks or 5½ weeks. Using 
LRC as endpoint, the results showed that patients whose 
tumors had high EGFR expression at IHC assay benefitted 
from a reduction in RT overall treatment time from 6½ to 
5½ weeks more than subjects with low EGFR levels.
Collectively, high EGFR expression may be useful 
for selecting HNSCC patients who will benefit from 
accelerated RT in terms of better LRC.
1B) COMBINATION OF SURGERY, 
RADIOTHERAPY AND CHEMOTHERAPY 
Prognosis
Among the studies that used binding assays, some 
investigated the role of EGFR within organ preservation 
strategies such as neoadjuvant CT followed by RT or 
concurrent CT/RT. No correlation between EGFR levels 
and response to these treatments was disclosed. However, 
with such technique, most studies reported a positive 
correlation between high concentrations of EGFR and 
poorer prognosis [28-32]. The binding assay confirmed 
also EGFR expression to be an independent prognostic 
factor of neck node relapse in HNSCC patients undergoing 
surgical resection ±RT [33]. 
The first attempts to establish a relationship between 
EGFR expression measured by IHC and PFS and OS 
were performed by two independent groups several years 
ago [34,35]. In both cases, high EGFR expression was a 
predictor of reduced DFS and OS at multivariate analysis. 
However, while Maiorano et al [34] analyzed by EGFR 
IHC a series of oral cavity SCC treated with surgery and 
scored samples as positive when presenting at least 10% 
of either membranous or cytoplasmic stain, Rubin Grandis 
et al [35] relied on an automated image analysis system 
(SAMBA) to quantify EGFR expression by IHC in the 
primary tumor of patients who underwent surgery ±RT 
and CT. 
More recently, the prognostic impact of EGFR 
protein level measured by quantitative approaches was 
confirmed by two independent studies which assessed 
EGFR expression through the AQUA method [36,37]. In 
particular, Psyrri et al [36] composed a tissue microarray 
of primary, non-metastatic oropharyngeal SSC treated with 
primary external beam RT or gross total surgical resection 
and postoperative RT (±CT). The AQUA scoring system 
showed that patients with high cytoplasmic or nuclear 
EGFR expression were more likely to experience local 
recurrence. In a tissue microarray composed of HNSCC 
treated with CTRT, AQUA analysis revealed EGFR 
protein levels as a strong predictor of patient outcome 
[37].
On the other hand, discordant results were obtained 
when EGFR expression was assessed by IHC without a 
quantitative approach. In most of the studies involving 
case series of HNSCC treated with surgery ±CT/RT, 
semi-quantitative criteria were adopted considering both 
intensity and extent of membranous staining. However, 
no real concordance in the scoring system across studies 
was disclosed. For this reason, a direct comparison 
of different studies could lead to misleading results. 
Furthermore, these series were published over several 
decades, with cases treated as late as in the ‘70s. It is 
therefore reasonable to assume that the increasing quality 
of treatment in recent years, especially for what concerns 
RT, might have influenced outcomes thus introducing 
other confounding factors in the comparison of these 
case series. Given these premises, some studies showed a 
statistical association between clinical outcome and EGFR 
overexpression [38-44], while other analyses failed to 
disclose such correlation [45-56]. A recent meta-analysis 
of 33 studies showed that although HNSCC patients with 
high EGFR expression had a poorer OS regardless of the 
type of treatment, a large heterogeneity was reported, 
mainly related to tumor site and IHC scoring system [57]. 
With respect to IHC, it is worth mentioning that when 
the studies were stratified according to the score systems, 
only the group that evaluated the staining based on a 
combination of intensity and extent showed significant 
association between EGFR expression and OS.
Two other studies investigated EGFR expression 
by IHC as a prognostic factor in patients treated with 
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combination of CT and RT [58, 59]. They used several 
different chemotherapeutic agents as well as different 
scoring system, none of them relying on a quantitative 
approach. These studies failed in identifying EGFR 
overexpression as a prognostic factor. A positive study 
is represented by the work of Kumar et al [60], who 
prospectively evaluated EGFR expression, together with 
other markers, in advanced oropharyngeal SCC patients 
treated with one cycle of cisplatin or carboplatin and 
fluorouracil. Responders (i.e., those with 50% response at 
the primary site) received CT/RT; non-responders received 
surgery and RT. EGFR overexpression was associated 
with poor response to induction CT. Similar results were 
reported by Hitt et al [61].
The issue of EGFR expression deserves a further 
comment relative to oropharyngeal cancer, given the 
strong association between these tumor sites and the 
presence of HPV conferring a favorable prognosis. Several 
studies did not investigate HPV infection, therefore 
potentially altering the evaluation of the prognostic value 
of EGFR expression. An inverse correlation between HPV 
positivity and EGFR expression has been reported [22, 50, 
Table 3: Main studies on EGFR gene copy number as prognostic and predictive factor in HSCC
Study Population Treatment EGFR assay Prognostic value of EGFR gain
Predictive 
value of 
EGFR gain
Radiotherapy 
Ryott 2009 n=37, oral tongue SCC Preoperative RT FISH assay No impact on pCR, OS -
Surgery, chemotherapy, radiotherapy
Chung 2006 n=75, HNSCC Surgery or biopsy FISH assay Impact on PFS, OS -
Temam 2007 n=134, HNSCC Surgery Quantitative real time PCR Impact on DFS, OS -
Nakata 2011 n=89, oral tongue SCC Surgery FISH assay Impact on DFS, OS -
Szabo 2011 n=71, HNSCC Surgery FISH assay Impact on OS -
Young 2011 n=240, HNSCC CRT FISH assay Impact on FFS -
Ryott 2009 n=65, oral tongue SCC Primary RT;surgery +/- RT and CT FISH assay No impact on OS -
Pectasides 2011 n=102, HNSCC Primary RT; surgery +RT FISH assay No impact on OS -
Wheeler 2012 n=154, HNSCC Surgery +/- RT;+/- CRT FISH assay No impact on PFS -
Huang 2012 n=160, oral cavity SCC Surgery FISH assay No impact on OS, DFS -
Dionysopulus 2013 n=253, larynx SCC Surgery and/or RT Real time PCR No impact on OS, DFS -
EGFR inhibitors
Hitt 2012 n=29, recurrent and/or metastatic HNSCC
Paclitaxel + 
Cetuximab FISH assay
No impact on 
response, OS,PFS -
Argiris 2010 n=39, HNSCC Docetaxel+cisplatin + Cetuximab FISH assay
No impact on PFS, 
OS -
Wheeler 2012 n=39, HNSCC Docetaxel+cisplatin + Cetuximab+RT FISH assay No impact on PFS -
Chau 2011 n=45 HNSCC Erlotinib +cisplatin FISH assay No impact on response, TTP, OS -
Cohen 2010 n=31, HNSCC Primary CT + CRT + Gefitinib FISH assay Impact on OS -
Licitra 2011 n= 312 recurrent and/or metastatic HNSCC
Platinum/5-FU +/- 
cetuximab FISH assay -
No 
association 
with 
response, 
PFS and OS
HNSCC: head and neck squamous cell carcinoma; OS: overall survival; PFS: progression free survival; RT: radiotherapy: 
CT: chemotherapy: CRT: chemotherapy; FISH: fluorescent in situ hybridization; FFS: failure free survival; pCR: pathological 
complete response; DFS: disease free survival; TTP: time to progression; -: the prognostic or predictive value of EGFR gene 
copy number was not investigated.
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62-68], but the same studies reported discordant results on 
the prognostic value of EGFR expression.
Few trials [60, 63, 64, 67] evaluated the combined 
effect of HPV status and EGFR expression on prognosis, 
showing that the use of EGFR expression in combination 
with HPV status provides additional prognostic 
information. The prognosis of patients with EGFR-
positive/HPV-negative cancer was the poorest, while 
the EGFR negative/HPV-positive group showed the best 
outcome. However, in recent studies on oropharyngeal 
HNC patients, the prognostic role of EGFR expression 
was related to the association with HPV-negative tumors, 
and the added value of EGFR analysis seems to be 
marginal in respect to HPV [22, 69].
1C) EGFR INHIBITORS 
Prognosis
Some studies have investigated the relation between 
EGFR expression and the outcome of recurrent/metastatic 
HNSCC patients treated with anti-EGFR antibody 
cetuximab [36, 70-72]. Even if limited to restricted series, 
these investigations consistently showed that EGFR levels 
detected by IHC have no impact on response, DCR, PFS 
or OS of patients treated with cetuximab. 
By contrast, when EGFR expression was assessed 
by IHC and real time PCR, a prognostic value for high 
EGFR expression has been associated with reduced PFS 
and complete response in cetuximab+RT-treated HNSCC 
patients, in two studies [73, 74]. 
However, in a phase II trial of induction CT with 
weekly cetuximab, paclitaxel, and carboplatin followed 
by chemoradiation in operable stage III/IV HNSCC, 
the identification of EGFR by a different approach, i.e. 
the quantitative AQUA method, confirmed the lack of 
prognostic value [75].
Last, the percentage of EGFR expression in the 
tumor cells was significantly associated with better OS in 
HNSCC patients receiving nimotuzumab in combination 
with CT [76], by contrast no association between EGFR 
expression and tumor outcome was observed in advanced 
HNSCC treated with nimotuzumab in combination with 
RT [77]. 
Prediction
In the EXTREME study, a trend to increased 
PFS and OS with cetuximab plus chemotherapy was 
observed for patients with higher IHC scores; however, 
the low number of patients does not allow any definitive 
conclusion [78]. The addition of cetuximab was able to 
counteract the dismal prognosis of the tumors with high 
EGFR expression showed by the group treated with 
chemotherapy alone. 
Discordant results were obtained in Burtness’ trial, 
in which patients were randomly assigned to receive 
cetuximab in combination with cisplatin or cisplatin 
alone [79]. Tumor samples were evaluated for EGFR 
cytoplasmatic expression by IHC and among the 52 
patients categorized as EGFR low-to-moderate, the 
response rate was 41% for those treated with cisplatin 
plus cetuximab, compared with 12% for those treated with 
cisplatin and placebo (p=0.03). Thus, low-moderate EGFR 
expression seems to predict the response to cetuximab. 
However, in a logistic regression analysis of response, the 
interaction between EGFR and treatment group was found 
not to be significant. By contrast, Psyrri et al reported a 
correlation between EGFR expression (AQUA method) 
and response to cetuximab [36]. In a trial of concurrent 
chemoradiation ± cetuximab in advanced HNSCC, the 
analysis was not able to identify EGFR expression as a 
predictive biomarker because outcomes did not improve 
by adding cetuximab to RT-cisplatin and did not differ 
according to EGFR expression [72]. Considering treatment 
with nimotuzumab, a significant survival improvement 
was observed in EGFR positive unresectable HNSCC 
patients treated with this inhibitor and RT compared to 
control patients receiving placebo and RT [80]. 
It is worth mention the work by Del Campo et al. 
who investigated lapatinib in locally advanced HNSCC 
before chemo-radiotherapy. They reported that IHC 
EGFR overexpression seems to be predictive; however, 
the number of responding patients was too low to make 
any conclusions [81]. 
On the basis of the above-mentioned discordant 
data, EGFR expression is neither a prognostic nor a 
predictive factor in relation to EGFR inhibitors use.
EGFR PROTEIN ACTIVATION 
Whereas many studies investigated the role of 
total EGFR expression, only few focused on quantitative 
evaluation of activated receptor (table 2), although 
phosphorylated EGFR (pEGFR) is thought to be a better 
biomarker for EGFR pathway activation. pEGFR can be 
assessed on frozen material by western blotting or reverse-
phase protein and on fixed material by array fluorescence 
resonance energy transfer (FRET) or IHC. 
2A) RADIOTHERAPY 
Prognosis
One recent case series investigated pEGFR 
expression via IHC on a population of oropharyngeal 
SCC treated in most cases with accelerated RT [82]. 
EGFR phosphorylation at residue Tyr1148 and Tyr1068 
was detected in 20% and 47% of patients, respectively; 
no association between Tyr1148 or Tyr1068 activation 
and OS or DFS was observed. Interestingly, pEGFR 
Tyr1148 and Tyr1068 were associated with absence of 
HPV infection. 
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Table 4: Main studies on EGFR polymorphisms, mutation and EGFR VIII expression as prognostic and predictive 
factor in HSCC
POLYMORPHISMS
Study Population Treatment EGFR assay Prognostic value
Surgery, chemotherapy, radiotherapy
Nai-Wen Su 2014 n=180, HNSCC Surgery +CRT PCR and sequencing Impact of EGFR R521K G/G and G/A on low OS
Bandrès 2007 n=67, HNSCC Surgery and/or CRT Fluorescent PCR; PCR-RFLP
Impact of EGFR R521K G/G on 
high DRM. No impact of (CA)n 
repeat polymorphism in intron 1 
on OS. 
EGFR inhibitors
klinghammer 2010 n=51, HNSCC Cetuximab+docetaxel PCR-RFLP; PCR and sequencing
Impact of R521K G/G on DCR 
and better PFS. No impact of of 
R521K G/G and (CA)n on OS.
Stoehlmacher-Williams J 
2012 n=48, HNSCC Cetuximab +/CT PCR-based RFLP
Impact of R521K G/G on longer 
OS
MUTATION
Surgery, chemotherapy, radiotherapy
Hama 2009 n=82, HNSCC Surgery +/- CRT PCR and sequencing Impact on longer survival without recurrence
Na 2007 n=108, tongue and tonsil SCC Surgery and or RT PCR and sequencing
No impact on OS
EGFR inhibitors
Bahassi 2013 Case report
Surgery and 
RT followed by 
cetuximab
PCR and sequencing Impact on response
Smilek 2012 n=29, HNSCC RT + cetuximab Real time PCR Impact on response
EGFR VIII EXPRESSION
Surgery 
Wheeler 2012 n=49, HNSCC surgery Quantitative real time PCR No impact on PFS
Szabo et al. n=71, HNSCC surgery IHC No impact on OS
EGFR inhibitors
Tinhofer 2011 n=45, HNSCC docetaxel+cetuximab IHC  impact on treatment response and PFS
Chau 2011 n=53, HNSCC erlotinib+cisplatin Real time PCR Impact on better DCR
Smilek n=29, HNSCC cetuximab +rt Real time PCR No impact on treatment response 
EGFR LIGAND EXPRESSION
Radiotherapy 
Aebersold 2002
n=95, 
oropharyngeal 
SCC
curative rt IHC No impact of TGFα on prognosis
Wen 1996 n=68 laryngeal SCC rt IHC Impact of TGFα on recurrence
Surgery 
Rubin 1998 n=91, HNSCC surgery+/-rt IHC Impact on DFS, cause specific survival
EGFR inhibitors
Tinhofer 2011 n=47, HNSCC cetuximab+docetaxel IHC Impact of amphiregulin on PFS, OS
HNSCC: head and neck squamous cell carcinoma; OS: overall survival; PFS: progression free survival; DRM: disease 
related mortality; DFS: disease free survival; DCR: disease control rate; RT: radiotherapy: CT: chemotherapy: IHC: 
immunohistochemistry; PCR: polymerase chain reaction; RFLP: restriction fragment length polymorphism 
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2B) SURGERY, CHEMOTHERAPY, 
RADIOTHERAPY 
Prognosis
Wheeler and colleagues, assessing the 
phosphorylation specific sites Y992 and Y1068 using 
reverse-phase protein array, showed that intermediate or 
high tumor EGFR Y1068, but not Y992, phosphorylation 
were associated with significantly reduced PFS in a series 
of frozen HNSCC samples [73]. Notably, in the same 
series, intermediate/high EGFR Y1068 phosphorylation 
and intermediate/high EGFR expression were both 
independently associated with reduced PFS, thus 
representing potential prognostic indicators. Y1068 
pEGFR was confirmed by western blotting in 17% of 
HNSCC patients who underwent surgery±CT where 
EGFR- phosphorylated tumors relapsed significantly 
earlier than not-phosphorylated ones [83]. 
Kong et al [84] investigated a large series of 
HNSCC via FRET, an automated technique able to inform 
about EGFR phosphorylation status. Of interest, EGFR 
activation did not correlate with EGFR expression, which 
in turn was not found to be prognostic. 
Last, in a single isolated study, pEGFR assessed 
by IHC using a specific antibody targeting the phospho-
tyrosine site 1086 was associated with prolonged survival 
[38].
2C) EGFR INHIBITORS 
Predictivity
No predictive effect was observed for pre-treatment 
pEGFR level in patients with locally-advanced HNSCC 
receiving lapatinib before chemo-radiotherapy [81]. 
EGFR GENE COPY NUMBER
In the studies reported in Table 3, EGFR gene 
status was assessed by FISH, and tumors showing high 
polysomy of chromosome or EGFR gene amplification 
were considered to have increased EGFR gene copy 
number and classified as FISH positive. 
3A) RADIOTHERAPY
Prognosis
In a study on oral tongue SCC patients treated with 
preoperative RT, high EGFR gene copy number tended to 
be higher in patients who did not achieve a pathological 
complete response, even if statistical significance was 
not reached [23]. The lack of other data does not allow to 
reach any definite conclusion.
3B) SURGERY, CHEMOTHERAPY, 
RADIOTHERAPY
Prognosis
A number of studies have investigated the 
association between EGFR gene status and prognosis 
in HNSCC patients on different primary treatments, and 
overall discordant results were obtained.
In some studies, increased EGFR gene copy number 
was considered as a strong prognostic factor, significantly 
associated with shorter PFS and OS [38, 46, 65, 84-86].
Interestingly, in all these studies EGFR gene copy 
number did not correlate either with EGFR protein 
expression assessed by IHC or EGFR mRNA expression 
levels detected by microarray or RT-PCR. The fact that 
EGFR copy number status is a more reliable indicator than 
EGFR overexpression was confirmed by the observation 
that patients whose tumors co-exhibited increase of 
EGFR gene copy number and protein overexpression 
presented significantly shorter OS than patients with 
tumors negative for FISH status and positive for EGFR 
protein overexpression [46]. These results indicate that the 
alteration of EGFR copy number may not be related only 
to alterations of EGFR protein expression. Indeed EGFR 
copy number changes frequently occur in association with 
chromosome 7 aneusomy that confers worse survival 
rates. Therefore one possibility is that additional genes 
on chromosome 7 that are co-amplified with EGFR 
may be involved in promoting a more aggressive tumor 
behavior. In line with this hypothesis, in a series of 35 
oral SCC patients, Gebhart found that a gain of short arm 
on chromosome 7 was linked to a higher rate of relapse 
and worse OS [87]. Alternatively, an increased EGFR 
copy number may be a surrogate marker of chromosomal 
instability, which confers an adverse prognosis in many 
tumors [88]. However, the mechanism by which EGFR 
FISH status contributes to the oncogenic effect in 
expressing cells remains unclear.
On the other hand, a number of studies reported lack 
of association between EGFR gene copy number and OS 
[23, 37, 40, 73, 89]. Of note, most of these studies also 
showed the correlation between EGFR gene copy number 
and EGFR protein expression levels. Thus, despite some 
studies are available, the actual prognostic value of the 
EGFR gene copy number remains controversial. However, 
when EGFR gene copy number was assessed by FISH, 
the different scores used to define the FISH-positive and 
negative cases could explain these inconsistent findings. 
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3C) EGFR INHIBITORS
Prognosis
The results obtained in different cohorts of locally-
advanced or recurrent HNSCC patients treated with 
cetuximab-based regimens indicate that patients with FISH 
positive tumors do not show a better response compared 
with FISH-negative subjects [70] and that EGFR gene 
status is not associated with PFS or OS [70, 73, 90]. 
Furthermore, EGFR amplification was not associated with 
TTP or OS also in HNSCC patients treated in two phase II 
trials on erlotinib [91]. By contrast, EGFR FISH-positive 
status was associated with shorter OS in locally-advanced 
HNC patients receiving CT/RT and gefitinib [92].
Prediction
The phase III EXTREME study demonstrated 
that combining cetuximab with platinum-based CT 
significantly prolonged OS in the first-line treatment 
of patients with recurrent and/or metastatic HNSCC 
compared with CT alone. Samples deriving from 
patients receiving cetuximab plus CT or CT alone were 
investigated by EGFR FISH to evaluate the role of 
increased EGFR copy number as predictive biomarker 
[93]. No correlation between EGFR FISH score and 
response rate was observed in both study arms: therefore, 
the results of this unique-to-date study support the lack of 
utility of EGFR FISH status in predicting the response to 
cetuximab. 
Furthermore, EGFR amplification showed no 
predictive role in patients treated with lapatinib in locally 
advanced HNSCC before chemio-radiotherapy [81]. 
EGFR POLYMORPHISMS
4A) SURGERY, CHEMOTHERAPY, 
RADIOTHERAPY
EGFR polymorphisms were uniformly assessed 
by DNA PCR-based methods. A recent study reported 
the prognostic role for EGF and EGFR polymorphisms 
in a cohort of locally-advanced HNSCC patients treated 
with post-operative CT-RT (Table 4) [94]. In more details, 
the 5-year OS rates of patients with EGFR R521K G/G 
(11.1%) and G/A (15.9%) were lower than those for the 
A/A (62.5%) genotype. Patients carrying one or two 
unfavorable alleles had worse 5- year OS than those 
without unfavorable allele (not available versus 20% 
versus 71.4%, p=0.002). Multivariate analysis revealed 
that the highest risk of death was associated with the 
coexistence of two unfavorable genotypes (hazard ratio 
25.7, 95% confidence interval =3.4–193.4; p=0.002). 
The prognostic value of EGFR R521K 
polymorphism was further investigated in the study of 
Bandrés et al., where it was defined as R497K according 
to the older nomenclature [95]. Patients with G/G 
genotype of the polymorphism R521K in exon 13 showed 
the highest risk of disease-related mortality. In contrast, in 
the same patient cohort, the (CA)n repeat polymorphism in 
intron 1 was not associated with OS. However, this single 
study does not allow any firm conclusion.
4B) EGFR INHIBITORS
Prognosis
Fifty-one recurrent/metastatic HNSCC patients 
enrolled in a single-arm, phase II study of second-line 
treatment with cetuximab/docetaxel were genotyped 
for EGFR polymorphisms R521K in exon 13 and (CA)
n repeat. The results revealed that R521K G/G genotype 
is significantly associated with increased skin toxicity, 
DCR and better PFS [96]. However, this genotype had no 
influence on OS. 
However, in HNSCC patients treated with 
cetuximab±CT, the presence of R521K G/G genotype was 
associated with longer OS. In detail, the median OS was 
6.7 months in patients with at least one K allele compared 
with 13.3 months in patients homozygous for the wild-
type R allele [97]. 
The CA repeat polymorphism was not associated 
with DCR, PFS or OS [96].
Table 5: Overview of Authors’ conclusions.
EGFR
expression activation copy number polimorphisms mutation EGFRvIII ligands
prog pred prog pred prog pred prog pred prog pred prog pred prog pred
RT yes yes (accelerated RT) no n.i. no n.i. n.i. n.i. n.i. n.i. n.i. n.i. d.r. TGFα n.i.
Surgery-CT-RT yes n.i. yes* n.i. d.r. n.i. yes R521K*  n.i. no n.i. d.r. n.i. yes TGFα* n.i.
EGFR inhibitors d.r. no n.i. n.i. no no yes R521K* n.i. weak evidence n.i. d.r. n.i.
yes 
amphiregulin* n.i.
prog: prognostic; pred: predictive; CT: chemotherapy; RT: radiotherapy; d.r.: discordant results; n.i.: not investigated; 
*:indicative results to be validated
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At present, the promising prognostic value of 
EGFR R521K G/G polymorphism in patients treated with 
combination of surgery, CT and RT or EGFR inhibitors 
deserves further investigations. The predictive role of 
these polymorphisms has not been investigated yet.
EGFR MUTATION
EGFR mutation is usually considered a rare event 
in HNSCC. However, the actual frequency of EGFR 
mutation is not well defined, even though analogous 
techniques, mainly PCR and sequencing, have been 
applied to investigate this issue [3, 98, 99].
5A) SURGERY, CHEMOTHERAPY, 
RADIOTHERAPY
Prognosis
Hama et al [83] prospectively analyzed a population 
of surgically-treated HNSCC (Table 4). Among 13 patients 
with EGFR phosphorylation, 4 with EGFR mutation had 
a longer survival without recurrence than patients with 
EGFR wild type (p=0.023). However, the mutational 
analysis performed on the largest number of cases (17 
mutated cases out of 108 total cases) indicated that EGFR 
mutation is not a significant prognostic factor [99].
5B) EGFR INHIBITORS
Prognosis
A case report showed complete response in a patient 
with HNSCC treated with cetuximab monotherapy after 
initial surgery and RT. The authors identified a somatic 
mutations in the ligand-binding domain (P546S) and in 
the kinase domain (R705G) [100]. Interestingly, in vitro 
experiments indicated that the P546S mutation in the 
EGFR ligand-binding domain enhances NIH-3T3 cell line 
sensitivity to cetuximab compared with cells expressing 
wild-type EGFR; on the other hand, R705G mutation did 
not seem to contribute to drug sensitivity. In another study, 
a deletion in exon 19 of EGFR was disclosed in two out of 
29 HNSCC patients treated with cetuximab and RT. These 
two patients presented poor clinical outcome, suggesting 
that this mutation may contribute to the limited response 
[74]. 
Despite this intriguing but overall weak evidence, 
it is rather unlikely that EGFR mutations could provide 
information about HNSCC response to anti EGFR therapy, 
mostly due to their low and variable rate in HNSCC. 
EGFRVIII EXPRESSION
6A) SURGERY, CHEMOTHERAPY , 
RADIOTHERAPY
Prognosis
EGFRvIII is a mutant form of EGFR due to a 
deletion of exons 2-7 resulting in a frame deletion variant 
with a truncated extracellular domain exerting ligand-
independent constitutive activity. 
Wheeler et al. investigated the expression levels of 
EGFRvIII mRNA, as detected by real time RT-PCR, in 
HNSCC patients treated with surgery and/or CT (Table 4) 
[73]. In this cohort of HPV-negative tumors, intermediate 
or high EGFRvIII mRNA levels did not provide any 
prognostic information.
Another study by Szabo et al evaluated EGFRvIII 
cell expression by IHC in a group of HNSCC patients [38]. 
Multivariate analysis showed no significant correlation 
between the presence of EGFRvIII and patient survival.
6B) EGFR INHIBITORS 
Prognosis
Biopsies from patients enrolled in a single-arm 
phase II study investigating cetuximab plus docetaxel 
as second-line treatment of recurrent/metastatic HNSCC 
were analyzed by IHC to measure EGFRVIII expression. 
EGFRvIII expression was detected in 17% of cases and 
there was a significant association between EGFRvIII 
levels and treatment efficacy. In the group of patients 
with low EGFRvIII IHC score, DCR was 65% whereas 
patients with high EGFRvIII score showed a DCR of 
13% (p=0.02). Multivariate logistic regression analysis 
confirmed the independent association of EGFRvIII 
with lack of response and shorter PFS [71]. Moreover, 
EGFRvIII level, detected by real time PCR, was associated 
with increased DCR but not with time to progression or 
OS in recurrent or metastatic HNSCC patients treated 
with erlotinib [91]. However, Smilek et al reported no 
association between RT-PCR detected EGFRvIII levels 
and response to cetuximab combined with RT [74].
It must be emphasized that the presence of 
EGFRvIII in HNSCC reported in the mentioned studies 
may be questioned. In fact, two studies recently analyzed a 
large number of tumors (638 and 531 HNSCC samples) for 
EGFRvIII expression using IHC with the antibody L8A4, 
RT-PCR and the RNA-Seq analysis [101, 102]. Both 
studies provided a strong evidence showing that EGFRvIII 
is absent or very rare (frequency of 0.37%) in HNSCC. In 
any case, when present, EGFRvIII expression level is low 
in HNSCC [103] and thus difficult to detect. Cumulatively, 
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the different methodologies applied, coupled with the 
intratumoral heterogeneity, may explain the discordant 
results and support the notion that an accurate detection of 
EGFRvIII needs multiple methodologies including DNA, 
RNA and protein assessment [103].
EGFR LIGAND EXPRESSION 
7A) RADIOTHERAPY
Prognosis
In a group of patients with oropharyngeal cancer 
who underwent curative RT, the levels of the EGFR ligand 
TGFα assessed by IHC in pretreatment tumor biopsies was 
not a prognostic marker (Table 4) [21]. By contrast, in a 
group of 68 patients with early laryngeal cancer treated 
with RT, the recurrence rate was significantly higher in 
patients with tumor showing TGFα expression detected 
by IHC [19].
7B) SURGERY, CHEMOTERAPY, 
RADIOTHERAPY 
Prognosis
TGFα levels were quantified by IHC and 
computerized image analysis system on primary tumors 
from HNSCC patients surgically treated (±RT-CT). At 
multivariate analysis, high TGFα levels were predictors 
of reduced DFS and disease-related mortality [35].
7C) EGFR INHIBITORS
Prognosis
Expression of the EGFR ligand amphiregulin was 
assessed by IHC on biopsies from recurrent/metastatic 
HNSCC patients treated with cetuximab plus docetaxel. 
A trend towards a reduction in DCR (40%) was observed 
(p=0.09) in patients with high amphiregulin IHC score, 
as compared with patients with low score (65%) [71]. 
In addition, patients that showed high expression of 
amphiregulin had significantly shorter PFS and OS. Due 
to the paucity of data, no firm conclusion can be made 
about the prognostic role of EGFR ligands.
CONCLUSION
We reviewed the literature on the clinical 
significance of EGFR alterations in relation to the HNSCC 
treatment, with the aim to identify emerging prognostic 
or predictive factors. Our conclusions are summarized in 
table 5.
The majority of the trials explored the prognostic 
role of EGFR alterations, while only limited data exist 
on the predictive role of EGFR alterations in relation to 
a specific treatment. At present, the predictive role of this 
marker has been exclusively explored in HNSCC patients 
treated with RT or EGFR inhibitors. 
Concerning RT, high EGFR expression is a 
negative prognostic factor associated with poor outcome. 
Convincing evidence supports the robust predictive role of 
high EGFR expression when evaluated by a quantitative 
assay, in order to select patients who can most benefit of 
accelerated RT. 
For HNSCC patients receiving multiple treatments 
such as surgery, CT and RT or a combination of them, 
no predictive biomarkers are available. However, several 
studies indicated that EGFR expression represents a good 
prognostic parameter, even if there is heterogeneity mainly 
due to IHC scoring system and tumor site variability. 
Notably, the significant association of high EGFR 
expression with shorter PFS and OS was reproducible only 
when protein expression was measured by a “quantitative” 
or at least semi-quantitative method. It appears advisable 
to estimate EGFR protein by a IHC method considering 
both intensity and extent of the staining, as well as 
stratifying patients by specific tumor sites. Nuclear 
EGFR and TGFα levels seem to be additional promising 
negative prognostic factors, as well as EGFR activation 
and polymorphisms, however they have not been widely 
validated yet. EGFR gene copy number as well as EGFR 
mutations has no prognostic value and do not deserve 
further investigation. 
Within the field of EGFR inhibitors, mainly 
cetuximab, available studies established that both EGFR 
expression and an increased gene copy number are 
neither predictive nor prognostic biomarkers. EGFR 
polymorphisms and high amphiregulin levels may be 
promising prognostic factors and validation trials are 
necessary. However, it must be taken into account that the 
immune system plays a role in the clinical response to the 
EGFR inhibitor cetuximab too. Indeed, in addition to the 
inhibition of downstream signaling pathways, cetuximab 
mediates its effects also by immunogenic mechanisms 
such as the antibody-dependent cell mediate cytotoxicity 
(ADCC), the complement-mediate cytotoxicity, the 
modulation of the human leukocyte antigen class I and 
antigen-processing machinery component expression 
[104]. This fact should be taken into account also 
considering the emerging role of checkpoint inhibitors in 
head and neck cancer and the possible synergistic effect 
of cetuximab and immunotherapeutic drug combinations.
Moreover, when interpreting these data, the 
inverse relationship between EGFR expression or EGFR 
increased gene copy number and the stronger prognostic 
factor of HPV positivity should be taken into account. 
HPV-positive oropharyngeal tumors tend to present 
decreased EGFR expression [50, 60, 63, 64, 67, 105], 
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and increased EGFR gene copy number is restricted to 
HPV-negative cancer [3, 65]. Although the rationale 
underlying those findings has not been fully elucidated 
yet, it is widely accepted that HPV-positive tumors have 
a different genetic profile compared with HPV-negative 
counterparts, thus contributing to the different clinical 
behavior and to the higher chemo- and radiosensitivity 
[68, 105, 106]. Therefore, the greater impact of EGFR 
deregulation in HPV negative tumors should be analyzed 
within the context of this different genetic pattern, and the 
“combined” effect of HPV status and EGFR expression on 
prognosis both of HPV-positive and negative or only of 
HPV-negative patients remains to be defined.
Lastly, it should be stressed the importance to 
increase the research regarding the molecular mechanisms 
underlying EGFR deregulation, in order to improve 
the HNSCC therapeutic approaches and to reduce the 
discrepancy sometimes existing between preclinical and 
clinical data.
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